Navigation Links
PRA Expands Operations in Europe
Date:5/21/2012

RALEIGH, N.C., May 21, 2012 /PRNewswire/ --  PRA, a leading Clinical Research Organization, announces the expansion of operations in The Netherlands (NL) and the United Kingdom (UK) to accommodate staff growth and strong client demand for our Phase IIa-IIIb service offerings.

Located in the thriving city of Utrecht, NL, this new Dutch facility will host 20+ employees and is the first PRA office in that region to primarily support Product Registration trials. Staff from our three other NL locations (Groningen, Zuidlaren and Assen) support early development and lab studies.

Previously, our Product Registration staff members in The Netherlands were either home-based or shared facilities with our Mechelen, Belgium employees. "But to better share best practices among employees, we felt that it was now necessary to provide a permanent office for the increasing Dutch Product Registration team," said PRA's Frank van de Wijngaert, Vice President and General Partner.

Also this month, PRA's 240+ employees in Reading, UK relocated to a larger, PRA-designed facility that offers additional room for increasing headcounts and provides modern facilities for client and project team meetings. The location also offers a first-class business park environment with excellent transportation links.

Since 2009, PRA has opened nine new offices in Europe, demonstrating our commitment to meeting our clients' diverse needs in a dynamic clinical trials environment.

About PRA

PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.

We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.

To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.


'/>"/>
SOURCE PRA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. S1 Biopharma Expands Focus to Include Male Sexual Health
2. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
3. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
4. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
5. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
6. Prasco Expands Authorized Generic Product Line with Vancocin® HCl Capsules
7. Precision Antibody Expands Antibody Characterization Services
8. QIAGEN Expands Access to State-of-the-art HPV Screening in China Through Co-marketing Agreement With KingMed Diagnostics
9. Synteract Expands Executive Roles to Support Growth
10. HRID Expands Distribution of Azul Instant™ Into Puerto Rico
11. Trovagene Expands Business Development Efforts Through a Partnership with Leomics Associates, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
(Date:4/19/2017)... -- Cardiology devices segment is anticipated to reach the highest ... Devices segment is likely to create absolute $ opportunity of ... 2017. By the end of 2027, Cardiology Devices segment is ... Mn, expanding at a CAGR of 18.4% over the forecast ... Pacific reprocessed medical devices market in terms of ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 26, 2017 , ... RawTrition now brings you BioEnergy which is a powder ... , RawTrition is taking nutrients to the next level! The superfoods ... its raw form (unlike the synthetically made options that are on the market). , ...
(Date:4/25/2017)... ... ... Bellus Medical, a leader in medical aesthetics, recently acquired ... photodynamic cosmetics (PDC). , Allumera® is the first PDC cream specifically formulated to ... minimize the appearance of pores – all with minimal downtime and results that ...
(Date:4/25/2017)... IN (PRWEB) , ... April 25, 2017 , ... ... D.C., CEOs, CFOs and HR decision-makers are preparing for how his administration could ... Financial will provide insight into what changes are most likely to make it ...
(Date:4/25/2017)... Switzerland (PRWEB) , ... April 25, 2017 , ... ... innovation targets, they rely on contracted partners to help with process innovation in ... of combined drug formulation experience along with state-of-the-art analytical equipment in support of ...
(Date:4/25/2017)... ... April 25, 2017 , ... Somnoware, a leading ... patient care management module. Using this new feature, sleep physicians can now predict ... on continuous positive airway pressure (CPAP), oral, or other forms of sleep apnea ...
Breaking Medicine News(10 mins):